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Abstract
Lysophosphatidic acid (LPA), a lipid mediator enriched in serum, stimulates cell migration, proliferation and other functions
in many cell types. LPA acts on six known G protein-coupled receptors, termed LPA1–6, showing both overlapping and
distinct signaling properties. Here we show that, unexpectedly, LPA and serum almost completely inhibit the transwell
migration of B16 melanoma cells, with alkyl-LPA(18:1) being 10-fold more potent than acyl-LPA(18:1). The anti-migratory
response to LPA is highly polarized and dependent on protein kinase A (PKA) but not Rho kinase activity; it is associated
with a rapid increase in intracellular cAMP levels and PIP3 depletion from the plasma membrane. B16 cells express LPA2,
LPA5 and LPA6 receptors. We show that LPA-induced chemorepulsion is mediated specifically by the alkyl-LPA-preferring
LPA5 receptor (GPR92), which raises intracellular cAMP via a noncanonical pathway. Our results define LPA5 as an anti-
migratory receptor and they implicate the cAMP-PKA pathway, along with reduced PIP3 signaling, as an effector of
chemorepulsion in B16 melanoma cells.
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Introduction
Lysophosphatidic acid (LPA) is a multifunctional lipid mediator
that stimulates migration, proliferation, survival and other
functions in many different cell types, both normal and malignant.
LPA acts through six known G protein-coupled receptors
(GPCRs), termed LPA1–6, which show both overlapping and
distinct signaling properties and tissue distributions [1,2]. The
three classical and best studied LPA receptors, LPA1–3, belong to
the so-called Edg subfamily of GPCRs. Three additional LPA
receptors, termed LPA4 (formerly P2Y9), LPA5 (GPR92) and
LPA6 (P2Y5) stand apart from the Edg family and are more closely
related to the purinergic receptor family, strongly suggesting that
LPA receptors have evolved from distinct ancestor genes [1,2].
LPA receptors couple to multiple G protein-effector pathways,
accounting for the multitude of cellular responses to LPA.
LPA is a major constituent of serum [3] and is produced
through the hydrolysis of lysophosphatidylcholine (LPC) by a
secreted lysophospholipase D, named autotaxin (ATX), originally
identified as a motility-enhancing factor for melanoma cells
(reviewed in [4,5]). The ATX-LPA signaling axis is of vital
importance for embryonic development [4] and is an effector of
tumor growth, angiogenesis and metastasis in mice [6–11].
Cell migration plays a key role in embryogenesis, tissue renewal,
immune responses and cancer metastasis. Most tumor cells,
including carcinoma, lymphoma, glioma and melanoma cells,
show an enhanced migratory response to LPA (positive chemo-
taxis) [12–17]. Where examined, LPA-induced migration is
primarily mediated by Edg-family LPA1 and LPA2 receptors and
involves both Gi- and G12/13-mediated signaling pathways. One
non-Edg-family receptor, notably LPA4, has been reported to
suppress cell migration [18]. In general, cell migration is driven by
pathways controlled by Rho GTPases and phosphatidylinositol 3-
kinase (PI3K), acting in a coordinate fashion to control the
spatiotemporal dynamics of cytoskeletal components. However,
soluble second messengers such as Ca
2+ [19,20] and cyclic AMP
(cAMP) [21,22] also play crucial roles in directing cell migration
and chemotaxis.
Here we show that, unexpectedly, LPA strongly impedes the
basal and growth factor-induced migration of B16F10 melanoma
cells. We show that the inhibitory effect of LPA is mediated by the
LPA5 receptor and that a rise in cAMP with consequent activation
of protein kinase A (PKA) is an important effector of LPA5-
mediated chemorepulsion, with a possible additional role for
reduced phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signaling.
Our results identify LPA5 as an anti-migratory receptor and they
point to a mechanism of LPA-induced chemorepulsion likely to be
relevant for tumor cells that predominantly express LPA5, acting
to override positive chemotactic signals.
Results and Discussion
LPA, serum and autotaxin inhibit B16 cell migration in a
highly polarized fashion
When testing various tumor cell types for their chemotactic
response to 1-oleoyl-LPA (LPA(18:1)) and serum (FCS) in transwell
assays, we found that B16F10 melanoma cell migration is strongly
inhibited by both FCS and LPA(18:1) (Figure 1A,B). Under serum-
free conditions, B16 cells show a high rate of basal, ‘spontaneous’
transwell migration during a 3 hr assay period. Addition of FCS or
LPAto the lowertranswell chamber inhibited the basal migration of
B16 cells almost completely. Half-maximal inhibitory effects were
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29260observed at ,100 nM LPA and 1% FCS (containing up to 50 nM
LPA; [3]) (Figure 1A,B). Strikingly, the inhibitory effects were
observed only when LPA and FCS were present in the bottom well
of the transwell chamber. LPA or serum added to the top well had
no detectable effect on cell migration, regardless of the concentra-
tionorthedirectionoftheLPAgradientacrossthefilter(Figure1C).
In other words, the inhibitory response to LPA is highly polarized.
In keeping with this notion, LPA had no detectable effect on the
random motility of B16 cells in low-density culture, as evidenced by
time-lapse video microscopy (not shown).
LPA is produced extracellularly from lysophosphatidylcholine
(LPC) by autotaxin (ATX). Addition of LPC(18:1) alone to the
lower chamber had no effect, but cell migration was significantly
inhibited when LPC was added together with recombinant ATX
(Figure 1D). Again, inhibition of migration was only observed
when ATX plus LPC were present in the lower chamber.
Even though the basal migration rate of B16 cells is already
high, it could be further enhanced by hepatocyte growth factor
(HGF). As shown in Figure 1E, LPA reduced the chemotactic
activity of HGF by some 60%, but only when both LPA and HGF
were present in the lower chamber. This result defines LPA as an
anti-chemotactic agonist for B16 cells. Based on these findings, we
conclude that LPA inhibits B16 cell migration in a highly polarized
fashion, likely reflecting localized LPA receptor signaling in the
extending pseudopodia.
We also tested the effect of LPA on B16 cell proliferation.
Melanomas are often characterized by activating mutations in B-
Raf, leading to constitutive activation of the mitogenic MAPK/
ERK1/2 pathway. B16F10 cells, however, express wild-type B-
Raf [23]. Consistent with their normal B-Raf status, B16 cells
showed very low basal MAPK/ERK1/2 activity, which was
strongly enhanced upon LPA addition (Figure 2A). Yet, LPA (up
to 10 mM) did not significantly affect the rate of B16 cell
proliferation, either in the presence or absence of limiting
concentrations of serum (Figure 2B).
Dissection of LPA signaling pathways: involvement of
cAMP and protein kinase A
We next set out to explore the signaling determinants of the
chemorepulsive effect of LPA. Optimal transwell migration was
observed with cells plated on fibronectin-coated membranes.
When B16 cells were plated on poly-L-lysine, which does not
interact with integrins, migration was similarly inhibited by LPA
(Figure 3A). Thus, the anti-migratory effect of LPA is independent
of the nature of the adhesive substrate and, by inference, does not
involve specific integrins.
Figure 1. LPA-induced inhibition of B16F10 cell migration. B16F10 cells were allowed to migrate for 3 hrs through fibronectin-coated 8 mm
porous membranes. A–B. Inhibition of cell migration by increasing concentrations of fetal calf serum (FCS) (A) or 1-oleoyl-LPA (B). The inset in B
shows a representative transwell filter after staining. C. Cell migration was assayed using LPA (1 mM) in either the upper or lower chamber, or in both
chambers, as schematically indicated by the red color. D. B16F10 cell migration in the presence of LPC (1 or 5 mM) with or without added
recombinant autotaxin (ATX; 10 nM) in the lower chamber. E. Enhanced cell migration (chemotaxis) induced by HGF (50 ng/ml) and inhibitory effect
of LPA (1 mM). Values are the means 6 SEM of at least three independent experiments and were normalized to the migration of non-stimulated cells
(*** P,0.0001).
doi:10.1371/journal.pone.0029260.g001
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toxin (PTX)-sensitive Gi proteins that couple to activation of Ras-
and Rac-mediated signaling pathways. Pretreatment of B16 cells
with PTX (200 ng/ml) did not affect the basal cell migration rate
nor its inhibition by LPA, which rules out the involvement of Gi-
linked pathways. In addition, we used the Rho-kinase (ROCK)
inhibitor Y27632, the protein kinase C inhibitor Ro-31-8220 and
two MEK inhibitors (PD598059 and U-0126), which were added
to both chambers. However, none of these inhibitors influenced
the anti-migratory effect of LPA during a 4 hrs time period (data
summarized in Table S1). The lack of effect of Y27632 is
somewhat unexpected, since the RhoA-ROCK pathway is known
to mediate contractile and anti-migratory events and, furthermore,
underlies LPA-induced chemorepulsion of neuronal growth cones;
in the latter case, Y27632 can even convert chemorepulsion into
chemoattraction [24]. We measured RhoA-GTP levels in B16 cells
before and after LPA stimulation, but were unable to detect a
significant effect of LPA on RhoA-GTP accumulation in these
cells (data not shown).
Given the multifunctional role of cAMP in cytoskeletal
regulation and cell migration, we tested the cAMP-raising agents
forskolin and 8-Br-cAMP. Both stimuli partly mimicked LPA in
inhibiting the basal migration rate of B16 cells (Figure 3B and
Table S1), indicating that cAMP is a candidate messenger for
mediating LPA-induced chemorepulsion. cAMP acts through
activation of protein kinase A (PKA), while at higher levels it exerts
additional effects through activation of Epac [25]. Epac is an
exchange factor for the Rap GTPase and is activated by direct
binding of cAMP. The PKA inhibitor H-89 attenuated the
inhibitory responses to LPA and forskolin without affecting the
basal migration rate (Figure 3C), whereas the Epac activator
8CPT-2Me-cAMP [26] had no detectable effect on cell migration
(Table S1). We confirmed that H-89 inhibits PKA activity by using
a FRET-based PKA sensor in forskolin-treated cells as described
previously [27].
To monitor changes in cAMP, we used the FRET-based cAMP
sensor CFP-Epac-YFP [27]. When expressed in mammalian cells,
CFP-Epac-YFP shows a significant FRET signal that rapidly
decreases upon a rise in cAMP [27]. In B16 cells expressing this
biosensor, LPA induced an initial transient rise in cAMP lasting for
about 5 min, followed by a prolonged phase of elevated cAMP
levels (Figure 4A,B). From these results we conclude that the
cAMP-PKA pathway, rather than the cAMP-Epac-Rap pathway,
contributes to LPA-induced chemorepulsion.
LPA-induced PIP3 depletion from the plasma membrane
In many cases, directed cell migration is critically dependent on
the lipid second messenger phosphatidylinositol (3,4,5)-trispho-
sphate (PIP3), which recruits PH-domain-containing proteins to
regulate F-actin remodeling and other key signaling events. Local
changes in PIP3 levels can be readily visualized by the
Figure 2. Effect of LPA on ERK1/2 activity and cell proliferation.
A. LPA-induced activation of ERK1/2 in B16F10 cells. Western blot
analysis of total ERK1/2 and phosphorylated ERK1/2 (MAPK), using anti-
ERK1/2 and anti-pERK1/2 antibodies. Cells were stimulated with the
indicated LPA concentration for the indicated periods of time. The blots
are representative of three independent experiments. B. Cells were
plated at day zero in medium containing 10% FCS. After 16 hrs, the cells
were exposed to medium containing 0.2% or 2% FCS, with or without
added LPA (10 mM). LPA was refreshed every 24 hrs and cells were
counted in triplicate. Values are the means 6 SEM (N=5).
doi:10.1371/journal.pone.0029260.g002
Figure 3. Effect of poly-L-lysine and cAMP reagents on cell migration. A. Inhibitory effect of LPA on B16F10 cells plated on poly-L-lysine-
coated membranes. B. Effects of forskolin (25 mM) and 8-Br-cAMP (100 mM) on transwelll migration of B16F10 cells. C. Effect of PKA inhibitor H-89
(30 mM) on cell migration in the presence or absence of LPA (1 mM). Values are the means 6 SEM (N=3; each experiment performed in quadruplo)
(**P,0.001; *** P,0.0001).
doi:10.1371/journal.pone.0029260.g003
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domains, such as the biosensor PH(GRP1)-GFP [28–30]. Most, if
not all, chemoattractants activate phosphoinositide 3-kinase (PI3K)
to induce rapid accumulation of PIP3 at the plasma membrane, as
detected by the translocation of PIP3-sensitive probes from the
cytosol to the plasma membrane [28–30]. Using PH-GRP1-GFP as
a biosensor, we found that non-stimulated B16 cells show already
relatively high basal PIP3 levels at the plasma membrane. LPA
triggered a rapid depletion of PIP3 from the plasma membrane as
inferred from the translocation of PH(GRP1)-GFP to the cytosol
(Figure 4C,D and Video S1). The PI3K inhibitor wortmannin
induced a more sustained depletion of PIP3 from the plasma
membrane (Figure 4C,D) and inhibited the basal migration of B16
cells (Table S1). We also examined the PIP3-dependent phosphor-
ylation state of Akt (protein kinase B) [31]. Consistent with the PIP3
imaging results, basal pAkt levels were high in non-stimulated B16
cells. LPA induced a modest fall in pAkt levels, while a PI3K
inhibitor reduced basal pAkt levels to almost zero (Figure S1).
It thus appears that LPA-induced chemorepulsion of B16 cells is
associated with (i) an increase in intracellular cAMP and (ii) PIP3
depletion from the plasma membrane. PIP3 depletion is not
secondary to a prior rise in cAMP levels, since the cAMP-raising
agonist a-melanocyte-stimulating hormone (a-MSH) (see below)
and forskolin failed to trigger PIP3 depletion (Figure 4D and data
not shown). Whether LPA-induced PIP3 depletion is due to
inhibition of basal PI3K activity or enhanced PIP3 phosphatase
activity, or both, remains to be determined.
Chemorepulsion is mediated by LPA5, an alkyl-LPA
preferring receptor
Which LPA receptor(s) mediate(s) the observed chemorepulsive
effect? Quantitative PCR analysis revealed that B16 cells co-
express LPA2, LPA5 and LPA6, with the relative expression levels
of LPA5 and LPA6 being much higher than that of LPA2
(Figure 5A). We used siRNA to knock down LPA5 and LPA6 and
assess the effects on migration. The inhibitory effect of LPA on cell
migration was largely abolished after knockdown of LPA5, but not
after knockdown of LPA6. LPA5 knockdown did not significantly
affect the basal cell migration rate, nor did it alter the expression
levels of LPA2 and LPA6 (Figure 5B,C). This strongly suggests that
LPA5 mediates the anti-migratory response of B16 cells.
Figure 4. LPA-induced changes in cAMP and PIP3 in B16 cells. A–B. Time course of LPA-induced changes in cAMP, monitored by using the
FRET-based sensor CFP-Epac-YFP. A. Time course of the separate CFP and YFP signals (blue and green, respectively). B. An increase in the ratio CFP/
YFP reflects an increase in [cAMP] (loss of FRET due to Epac unfolding [27]). LPA, 1 mM; forskolin (10 mM) was used to calibrate the response.
C. Confocal images of LPA- and wortmannin-induced loss of PIP3 from the plasma membrane, as inferred from the translocation of PH(GRP1)-GFP to
the cytosol. See also Video S1. D. Agonist-induced increase in cytosolic PH(GRP1)-GFP fluorescence, reflecting loss of PIP3 from the plasma
membrane. Dynamic changes in fluorescence intensity (relative to non-stimulated control) were quantified using ImageJ software. LPA, 1 mM;
wortmannin, 500 nM; a-MSH, 1 mM.
doi:10.1371/journal.pone.0029260.g004
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linked LPA over the more common ester-linked LPA molecular
species [32,33]. We therefore compared the efficacy of LPA(18:1)
to that of the corresponding ether-linked analog 1-O-alkyl-
LPA(18:1). As shown in Figure 5D, alkyl-LPA(18:1) was ,10-fold
more potent than acyl-LPA(18:1) in inhibiting cell migration (IC50
,10 nM versus 100 nM). This difference in potency cannot be
reconciled with Edg-family LPA receptors (LPA1-3), which prefer
the acyl forms of LPA. This result confirms critical involvement of
LPA5 in mediating the anti-migratory response to LPA.
To further establish the anti-migratory potential of LPA5,w e
evaluated LPA5 in HeLa cells. These cells express LPA1,L P A 2
and LPA5 at about equal mRNA levels (Figure 6A), while their
basal migration rate is very low (Figure 6B). LPA induced a
robust chemotactic response in HeLa cells. In LPA5-overexpress-
ing HeLa cells, however, LPA-induced chemotaxis was signifi-
cantly reduced (Figure 6B). These results support the view that
the relative expression pattern of LPA receptors in a given cell
type determines migration outcome. That is, the chemorepulsive
activity of LPA is observed in those cells where LPA5 is the
predominant receptor, overriding the chemoattractant activity of
LPA1 and LPA2.
LPA5 mediates an increase in cAMP
Thus far, the signaling properties of LPA5/GPR92 have been
inferred from heterologous expression studies [34–37]. LPA5/
GPR92-transfected B103 neuroblastoma cells undergo cytoskeletal
contraction (Rho kinase-dependent), Ca
2+ mobilization and an
increase in cAMP after LPA addition, whereas control B103 cells
do not [35]. The rise in cAMP is not mediated by the canonical
Gas pathway, but most likely involves bc subunits; there is no
evidence for LPA5 coupling to Gi pathways [35].
To assess whether the increase in cAMP in LPA-treated B16
cells (Figure 4B) is mediated by LPA5, we monitored cAMP levels
in LPA5-depleted B16 cells. While the LPA-induced rise in cAMP
was not affected in cells treated with non-targeting siRNA, it was
absent in LPA5 knockdown cells (Figure 7A,B), indicating that
LPA5 mediates the cAMP signal. We next expressed LPA5 in
HEK293 cells, as these cells do not normally show a rise in cAMP
upon LPA stimulation (Figure 7C). In LPA5-transfected HEK293
cells, LPA evoked a significant increase in cAMP with kinetics
similar to those observed in B16 cells (Figure 7D).
Taken together, these results demonstrate that LPA5 is a cAMP-
elevating receptor, both in its native cellular context and in
transfected cells, and they reinforce the notion that the anti-
Figure 5. Evidence for LPA5 mediating inhibition of cell migration. A. LPA receptor expression in B16F10 cells as determined by qPCR.
GPR87 is a putative LPA receptor that awaits validation [49]. B. Knockdown of LPA5 and LPA6 expression using specific siRNA pools (see Materials and
Methods). Values are relative to GAPDH mRNA levels (A) or as percentage (B). Values are the means 6 SEM (N=5). C. Migration of B16F10 cells
transfected with siRNA against LPA5 or LPA6, or a non-targeting siRNA (control), in the presence or absence of LPA. Relative values are the means (6
SEM) of two independent experiments each performed in quadruplo (*** P,0.0001). D. Inhibition of cell migration by increasing concentrations of 1-
oleoyl-LPA and 1-alkyl-LPA(18:1). IC50 values: alkyl-LPA(18:1) ,10 nM; LPA(18:1) ,100 nM.
doi:10.1371/journal.pone.0029260.g005
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e29260Figure 7. Rise in cAMP mediated by LPA5. Cells transfected with CFP-Epac-YFP were stimulated with LPA (1 mM) and forskolin (10 mM) as
indicated. The traces depict a cAMP-induced loss of FRET (unfolding of Epac) as an increase in CFP/YFP ratio [27]. A. B16 cells transfected with non-
targeting siRNA. B. B16 cells transfected with siRNA against LPA5. D. Wild-type HEK293T cells. E. HEK293T cells transfected with LPA5. All traces are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0029260.g007
Figure 6. Reduced chemotactic response to LPA in LPA5-transfected HeLa cells. A. LPA receptor expression in HeLa cells as determined by
qPCR. GPR87 is a putative LPA receptor that awaits validation [49]. B. Wild-type or HA-LPA5-transfected Hela cells were allowed to migrate for 24 hrs
in the presence or absence of LPA (1 mM) as indicated. Note reduced chemotaxis in the LPA5 transfectants. Values are normalized to migration of
unstimulated cells (means 6 SEM; N=4).
doi:10.1371/journal.pone.0029260.g006
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rise in cAMP with subsequent activation of PKA.
Comparing LPA to a-MSH and sphingosine 1-phosphate
To confirm that cAMP serves as an anti-migratory signal we
used a-MSH, an agonist of Gas-coupled melanocortin receptors. It
has been reported that a-MSH suppresses the metastatic potential
of B16 cells but does not affect their proliferation [38]. a-MSH
induced a very rapid and prominent increase in cAMP
(Figure 8A,B) and partly inhibited B16 cell migration, regardless
of whether a-MSH was present in the lower or upper chamber
(Figure 8C); the latter result clearly differs from LPA action. The
anti-migratory effect of a-MSH was less pronounced than
observed with LPA, while the rise in cAMP is more rapid and
more sustained, similar to what is observed with forskolin. The
marked difference between the a-MSH- and LPA-induced cAMP
signals must reflect a fundamental distinction between the
canonical (as) and the noncanonical (bc) pathway, respectively,
by which GPCRs can stimulate cAMP production. Together,
these results support the view that cAMP is an anti-migratory
signal for B16 cells. However, a-MSH and forskolin appear to act
globally, whereas LPA signals in a polarized manner. Further-
more, LPA triggers PIP3 depletion from the plasma membrane,
whereas a-MSH does not (Figure 4D).
Inhibition of B16 cell migration is also induced by sphingosine
1-phosphate (S1P), acting through the S1P2 receptor, which has
been associated with altered Rac/Rho-kinase signaling [39].
Unlike LPA, however, S1P inhibited B16 cell migration when
the agonist was present alone in the upper chamber; furthermore,
S1P failed to affect basal cAMP levels in B16 cells (Figure S2). This
suggests that S1P2 and LPA5 differ fundamentally in their anti-
migratory signaling mechanisms.
LPA5 subcellular localization
Next, we asked whether the polarized response of B16 cells to
LPA is attributable to an asymmetrical distribution of LPA5.
Certain GPCRs show a polarized subcellular localization as
exemplified by the P2Y receptor family [40]. In MDCK epithelial
cells, a subset of P2Y receptors resides at the basolateral
membrane, while other P2Y members are only found at the
apical plasma membrane [40]. We examined the distribution of
HA-tagged LPA5 in MDCK, HeLa and B16 cells. However, none
of these cell types showed a clear asymmetric distribution of LPA5
(Figure S3). We therefore assume that the polarized response of
migrating B16 cells to LPA is a reflection of localized effector
pathways in the pseudopodia, rather than of localized LPA5
expression.
Conclusions
How does the cAMP-PKA pathway, with a possible additional
role for reduced PIP3 signaling, contribute to the chemorepulsive
effect of LPA5? PKA can exert both stimulatory and inhibitory
effects on cytoskeletal dynamics and cell migration [41], but its
action is very complex since PKA acts on numerous target proteins
depending on agonist, cell type and subcellular localization of
PKA [42]. In epithelial cells, the PKA catalytic subunit (encoded
by PRKCA) emerged as an anti-migratory gene from RNAi screens
[43,44]. In fibroblasts and carcinoma cells, the cAMP-PKA
pathway can inhibit cell migration by interfering with lamellipodia
formation [45]. Other studies show that PKA is enriched in
protrusive pseudopodia [46,47], but the specific PKA substrates
remain to be identified. Inhibition of cell migration by LPA5 most
likely occurs through PKA-mediated and PIP3-dependent mod-
ulation of components in the Rho/Rac and cytoskeletal assembly
pathways. Localized PKA activation, along with PIP3 depletion,
would then lead to destabilization and retraction of extending
pseudopodia.
Chemoattractants and repellents cooperate during tumor cell
migration and metastasis, and hence the outcome of cell migration
is dictated by the relative expression levels of individual receptors.
While the precise mechanisms underlying LPA5-mediated che-
Figure 8. Effects of a-MSH on cAMP and cell migration. A–B.
B16F10 cells, expressing CFP-Epac-YFP, were stimulated with a-MSH
(1 mM), LPA (1 mM) and forskoIin (10 mM) as indicated. C. Inhibition of
transwell migration by a-MSH, when present in either the upper or the
lower chamber as illustrated.
doi:10.1371/journal.pone.0029260.g008
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warrant further studies on the expression patterns and clinical
outcome of LPA5 in melanoma and other cancers. By inhibiting
cell migration, LPA5-selective agonists might have therapeutic
potential for those tumors in which LPA5 is a predominant
receptor. Caution will be needed, however, since LPA5 signaling
may also impact on platelet and mast cell functions [32,33,48].
Materials and Methods
Cell culture and materials
B16F10 melanoma cells were obtained from the American Type
Culture Collection (ATCC cat. no. CRL-6475). Cells were
cultured in DMEM (Dulbeccos’ Modified Eagle Medium)
supplemented with 10% fetal calf serum (FCS), L-glutamine and
antibiotics. Lysophospholipids were purchased from Avanti Polar
Lipids, Inc.; HGF and a-MSH were from Sigma-Aldrich.
PH(GRP1)-GFP plasmid was kindly provided by T. Balla (NIH,
Bethesda, MD, USA).
RNA isolation and real-time PCR
Total RNA was extracted using RNeasy Micro Kit (Qiagen).
cDNA was synthesized by reverse transcription from 2 mg RNA
using oligodT 15 primer and SSII RT enzyme (InVitrogen). RT-
qPCR was performed on a 7500 Fast System (Applied Biosystems)
as follows: 95uC for 2 min., 95uC for 10 min., 40 cycles at 95uC
for 15 sec. followed by 60uC for 1 min. for annealing and
extension. The final reaction mixtures (20 ml) consisted of diluted
cDNA, 16SYBR Green Supermix (Applied Biosystems), 200 nM
forward primer and 200 nM reverse primer. Reactions were
performed in 96-well plates in duplicate. Primer sequences are
listed in Table S2.
RNA interference and transfections
siRNA pools specific for LPA5 and LPA6 and non-targeting
siRNAs were purchased from Dharmacon, Inc. B16F10 cells were
transfected with 2 mM siRNA using Dharmafect-2 according to
the manufacturer’s protocol. Cells were used 3 days after
transfection. Transfections of LPA5 and CFP-Epac-YFP plasmids
were done using Fugene according to the manufacturer’s protocol,
using 10 mg of DNA on 25 ml of Fugene for a 10-cm dish with
3610
6 cells in suspension. Transfection efficiency was determined
by side-by-side transfection with GFP and was typically around
75%. PH(GRP1)-GFP was transfected into B16F10 cells using
Fugene according to the manufacturer’s protocol, using 1 mgo f
DNA on 3 ml of Fugene6 per well on a 6-well plate. Efficiency was
typically around 30%.
Cell migration assays
Cell migration was measured using 48-well chemotaxis
chambers (Neuro Probe, Inc.) equipped with 8 mm-pore polycar-
bonate membranes, which were coated with either fibronectin or
poly-L-lysine (20 mg/ml). Cells (1610
6/ml) were added to the
upper chamber. Fatty acid-free BSA (1 mg/ml) was used as a
lysophospholipid carrier. Migration was allowed for 3 hrs for
B16F10 and 24 hrs for HeLa cells at 37uC in humidified air
containing 5% CO2. Migrated cells were fixed in Diff-Quik Fix
and stained using Diff-Quik II. Migration was quantified by color
intensity measurements using TINA software.
Western blotting
Cells were washed in ice-cold PBS (phosphate-buffered saline
containing 2 mM Ca
2+ and Mg
2+), lysed in RIPA buffer with
protease inhibitors and spun down. 15 ml of lysate was loaded onto
a 4–12% NuPageH Bis-Tris Gel. Electrophoresis was carried out at
200 V for 40 min in NuPageH MOPS running buffer. Protein was
transferred to a nitrocellulose membrane using the iBlotH Dry
Blotting System. The membrane was blocked for 1 hour at room-
temperature in 50 mg/ml non-fat milk powder in TBST.
Incubation with antibodies was done overnight at 4uC. Proteins
were visualized using chemiluminescence.
Monitoring cAMP
Intracellular cAMP levels were monitored in real-time using the
FRET-based CFP-Epac-YFP sensor, as described [27]. Transfect-
ed cells on coverslips were placed on an inverted NIKON
microscope and excited at 425 nm. Emission of CFP and YFP was
detected simultaneously through 470620 and 530625 nm band-
pass filters. Data were digitized and FRET was expressed as the
ratio of CFP to YFP signals, the value of which was set to 1.0 at the
onset of the experiments. Changes were measured as percentage
deviation from this initial value.
PIP3 imaging
Agonist-induced changes in the levels of phosphatidylinositol
(3,4,5)-trisphosphate (PIP3) in the plasma membrane were
monitored using a biosensor consisting of the PIP3-specific PH
domain of GRP1 (general receptor for phosphoinositides-1) fused
to GFP, PH(GRP1)-GFP [28]. PH(GRP1)-GFP-transfected
B16F10 cells were grown on glass coverslips and serum starved
overnight. Live-cell imaging was done on a Leica TCS SP2
confocal microscope equipped with an Ar 488 laser system. Images
were taken using a 636 NA 1.32 objective. Coverslips were
mounted in a metal ring system and buffer was applied (140 mM
NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM CaCl2,2 3 m M
NaHCO3, 10 mM HEPES, 10 mM glucose). Cells were selected
randomly. Agonists were added while images were collected at
appropriate time intervals (2–7.5 sec).
Supporting Information
Figure S1 Effect of LPA on pAkt levels in B16F10 cells. A.
Western blot showing the phosphorylation status of Akt (pAkt;
Ser473) in non-stimulated and LPA-stimulated B16F10 cells, in
the presence or absence of PI3K inhibitor LY294002 (10 mM) as
indicated. B. Quantification (using TINA software) of the pAkt
bands in (A) relative to total Akt.
(TIF)
Figure S2 Effect of sphingosine 1-phosphate (S1P) on
cAMP levels in B16F10 cells. Cells were transfected with the
CFP-Epac-YFP cAMP sensor. S1P, 1 mM; forskolin, 10 mM.
(TIF)
Figure S3 Subcellular localization of LPA5 in diverse cell
types. Confocal images of MDCK, HeLa and B16F10 cells
tranfected with HA-tagged LPA5 and stained for HA (and ZO-1 in
MDCK cells) to visualize the localization of LPA5. Cells were fixed
andpermeabilized with methanolat220uC.Donkeyanti-ratA-488
(for LPA5) and goat anti-mouse A-594 (for ZO-1) were used as
secondary antibodies. Side-views are shown in the right and bottom
lanes using Z-stack projections. HA-LPA5 in green; ZO-1 in red.
(TIF)
Table S1 Effect of various reagents on B16F10 cell
migration.
(DOC)
Table S2 Primer sequences used for qPCR.
(DOC)
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membrane. Movie showing LPA-induced loss of PH(GRP1)-
GFP from the plasma membrane in LPA-treated B16F10 cells.
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